This study is researching the effect of 20 mg Vonoprazan compared to placebo on the treatment of EoE. For those diagnosed with EoE and are interested in a pill treatment study.

We are looking for volunteers to join our study. We want to see if a medicine called itraconazole can help stop a condition called Barrett's Esophagus (BE) from coming back after treatment. This study will help us learn if itraconazole is safe and how it works compared to a pretend pill with no medicine, called a placebo. If you join, you will get either itraconazole or the placebo. Your participation will help us understand more about keeping BE from returning.

A study to confirm the safety and effectiveness of a medication to help with alcohol-related liver disease in adults between 18 and 65 years old.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with Compensated Cirrhosis due to NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

The purpose of this study is to compare the effects of the research medicine, solrikitug, with a placebo to find out which is better for treating eosinophilic esophagitis (EoE) in adult patients. The purpose is to see if the research medicine helps improve EoE symptoms: dysphagia (difficulty swallowing), tissue inflammation, clinical symptoms and quality of life.

We are studying an investigational drug, Efruxifermin, to see if it will help in the treatment of liver inflammation and scarring (fibrosis) in adults diagnosed with NASH (non-alcoholic steatohepatitis) and MASH (metabolic dysfunction-associated steatohepatitis).

Do you have Alpha-Gal Allergy AND GI symptoms such as abdominal pain, vomiting, and diarrhea? Have you experienced improvement of these symptoms on a mammalian meat-free diet? You may be eligible for our study to help UNC researchers better understand alpha-gal allergy with belly/gastrointestinal symptoms. Compensation provided.

To determine the effect of an FDA-approved drug on treating patients with severe strictures and Eosinophilic Esophagitis (EoE)

People with Barrett's esophagus are at higher than average risk of developing esophageal cancer. Obeticholic Acid (OCA) is a medication similar to bile acids (a fluid made and released by the liver). OCA binds to a group of cells in the intestine that is believed to have a positive effect on preventing cancer development. The purpose of this study is to compare the safety and effects of OCA with that of a placebo on the risk of developing esophageal cancer in people with Barrett's esophagus.

We have study goals: (1) To conduct phone interviews to ask about symptoms and life impact from adult patients living with PSC; (2) To lead community advisory board discussions to decide on using existing symptom measures 'as is', modify existing measures or develop new measures to evaluate PSC symptoms; and (3) To conduct interviews with adult patients with PSC to assess their understanding and comprehension of selected symptom measures. We plan to consent and enroll up to 75 patients into a Screening database. From the database, we will select up to 24 patients to interview for Aim 1 and up to 16 patients to interview for Aim 3. Interviews will be conducted over the phone by staff at Duke University. At the end of the study, we will have 3 PSC symptom measures for use in future PSC studies.